Alpha 2.0
Login Register
» Authors » Jaime Vilar-Alejo

Jaime Vilar-Alejo

Explore the profile of Jaime Vilar-Alejo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 92
Followers 0
Related Specialty
Dermatology
Top 10 Co-Authors
Enrique Herrera-Ceballos
Ignacio Garcia-Doval
Merce Alsina
Gregorio Carretero
Esteban Dauden
Raquel Rivera
Carmen Garcia-Donoso
Enrique Herrera-Acosta
Mar Llamas-Velasco
Antonio Sahuquillo-Torralba
Published In
Acta Derm Venereol
J Am Acad Dermatol
Eur J Dermatol
Australas J Dermatol
Arch Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa J, Dauden E, Herrera-Acosta E, et al.
J Dermatolog Treat . 2021 Apr; 33(4):2110-2117. PMID: 33913796
Background: Limited information is available regarding the risk of incident liver disease in patients with psoriasis receiving systemic therapies. Objectives: To describe the liver safety findings of conventional and modern...
2.
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Hernandez-Fernandez C, Carretero G, Rivera R, Ferrandiz C, Dauden E, de Cueva P, et al.
Acta Derm Venereol . 2020 Dec; 101(1):adv00354. PMID: 33269405
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients...
3.
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Baniandres-Rodriguez O, Vilar-Alejo J, Rivera R, Carrascosa J, Dauden E, Herrera-Acosta E, et al.
J Am Acad Dermatol . 2020 Oct; 84(2):513-517. PMID: 33122022
No abstract available.
4.
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Dauden E, Carretero G, Rivera R, Ferrandiz C, Llamas-Velasco M, de la Cueva P, et al.
J Am Acad Dermatol . 2020 Mar; 83(1):139-150. PMID: 32213306
Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab,...
5.
Migratory, recurrent skin eruption in a returning traveller
Grau-Perez M, Vilar-Alejo J, de la Rosa-Del Rey M, Hernandez-Febles M, Perez-Arellano J
Australas J Dermatol . 2018 Jun; 59(4):e307-e308. PMID: 29869372
No abstract available.
6.
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo J, et al.
Arch Dermatol . 2012 Apr; 148(4):463-70. PMID: 22508869
Objective: To describe the use of systemic therapy for psoriasis (biologic and nonbiologic [classic] drugs) in patients not adequately represented in randomized controlled trials (RCTs) and the risk of serious...
7.
SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept
Vilar-Alejo J, Dehesa L, de la Rosa-del Rey P, Novoa-Medina J, Valeron Almazan P, Santana Medina N, et al.
Acta Derm Venereol . 2010 Sep; 90(5):531-2. PMID: 20814638
No abstract available.
8.
Vesicular Sézary syndrome with bullous lesions on the feet
Dehesa L, Bastida J, Camacho-Galan R, Campos-Adsuar C, Gomez-Duaso J, Vilar-Alejo J
Eur J Dermatol . 2009 Mar; 19(3):282-3. PMID: 19258239
No abstract available.